Nyla A. Heerema

40.3k total citations · 4 hit papers
357 papers, 16.5k citations indexed

About

Nyla A. Heerema is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Nyla A. Heerema has authored 357 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Public Health, Environmental and Occupational Health, 145 papers in Hematology and 123 papers in Genetics. Recurrent topics in Nyla A. Heerema's work include Acute Lymphoblastic Leukemia research (171 papers), Chronic Lymphocytic Leukemia Research (117 papers) and Acute Myeloid Leukemia Research (93 papers). Nyla A. Heerema is often cited by papers focused on Acute Lymphoblastic Leukemia research (171 papers), Chronic Lymphocytic Leukemia Research (117 papers) and Acute Myeloid Leukemia Research (93 papers). Nyla A. Heerema collaborates with scholars based in United States, Canada and United Kingdom. Nyla A. Heerema's co-authors include John C. Byrd, Harland N. Sather, Paul S. Gaynon, Gail H. Vance, Octavian Henegariu, Clara D. Bloomfield, Krzysztof Mrózek, Meenakshi Devidas, Andrew J. Carroll and Amy J. Johnson and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Nyla A. Heerema

350 papers receiving 16.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice

2006 795 citations Nyla A. Heerema et al. profile →
Multiplex PCR: Critical Parameters and Step-by-Step Protocol

1997 743 citations Octavian Henegariu, Nyla A. Heerema et al. profile →
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

2014 304 citations Kirk R. Schultz, Andrew J. Carroll et al. Leukemia profile →

Peers

Countries citing papers authored by Nyla A. Heerema

Since Specialization

Citations

This map shows the geographic impact of Nyla A. Heerema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nyla A. Heerema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nyla A. Heerema more than expected).

Fields of papers citing papers by Nyla A. Heerema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nyla A. Heerema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nyla A. Heerema. The network helps show where Nyla A. Heerema may publish in the future.

Co-authorship network of co-authors of Nyla A. Heerema

This figure shows the co-authorship network connecting the top 25 collaborators of Nyla A. Heerema. A scholar is included among the top collaborators of Nyla A. Heerema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nyla A. Heerema. Nyla A. Heerema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse 2023 ·Journal of Clinical Oncology ·Laura Hogan, Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Teena Bhatla, Michael J. Borowitz, Elizabeth A. Raetz, Andrew J. Carroll, Nyla A. Heerema, Gerhard Zugmaier, Elad Sharon, M. Brooke Bernhardt, Stephanie Terezakis, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh	33
2	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232 2021 ·Leukemia ·Michael J. Burke, Meenakshi Devidas, Zhiguo Chen, Wanda L. Salzer, Elizabeth A. Raetz, Karen R. Rabin, Nyla A. Heerema, Andrew J. Carroll, Julie M. Gastier‐Foster, Michael J. Borowitz, Brent L. Wood, Naomi Winick, William L. Carroll, Stephen P. Hunger, Mignon L. Loh, Eric Larsen	12
3	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 2021 ·Journal of Clinical Oncology ·Leonard A. Mattano, Meenakshi Devidas, Kelly W. Maloney, Cindy Wang, Alison M. Friedmann, Patrick J. Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie M. Gastier‐Foster, Nyla A. Heerema, Nina S. Kadan‐Lottick, Yousif Matloub, David T. Marshall, Linda C. Stork, Mignon L. Loh, Elizabeth A. Raetz, Brent L. Wood, Stephen P. Hunger, William L. Carroll, Naomi Winick	22
4	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib 2021 ·Blood ·Adam S. Kittai, Cecelia Miller, (unknown), Ying Huang, Lynne V. Abruzzo, Kyle A. Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach	31
5	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study 2020 ·Clinical Cancer Research ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien	126
6	CytoGPS: a web-enabled karyotype analysis tool for cytogenetics 2019 ·Bioinformatics ·Zachary B. Abrams, (unknown), Lynne V. Abruzzo, Nyla A. Heerema, (unknown), (unknown), (unknown), Kevin R. Coombes, Philip Payne	8
7	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 2019 ·Blood ·Anne Angiolillo, Reuven J. Schore, John A. Kairalla, Meenakshi Devidas, Karen R. Rabin, Patrick A. Zweidler‐McKay, Michael J. Borowitz, Brent L. Wood, Andrew J. Carroll, Nyla A. Heerema, Mary V. Relling, (unknown), Kelly W. Maloney, Cindy Wang, William L. Carroll, Naomi Winick, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger	4
8	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials 2018 ·British Journal of Haematology ·Jeffrey A. Jones, Anthony R. Mato, Steven Coutré, John C. Byrd, Richard R. Furman, Peter Hillmen, Anders Österborg, Constantine S. Tam, Stephan Stilgenbauer, William G. Wierda, Nyla A. Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D. Chu, Danelle F. James, Susan O’Brien	32
9	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2017 ·Clinical Cancer Research ·Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, (unknown), Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien	47
10	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131 2017 ·Cancer ·Wanda L. Salzer, Michael J. Burke, Meenakshi Devidas, Si Chen, Lia Gore, Eric Larsen, Michael J. Borowitz, Brent L. Wood, Nyla A. Heerema, Andrew J. Carroll, Joanne M. Hilden, Mignon L. Loh, Elizabeth A. Raetz, Naomi Winick, William L. Carroll, Stephen P. Hunger	39
11	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232 2016 ·Journal of Clinical Oncology ·Eric Larsen, Meenakshi Devidas, Si Chen, Wanda L. Salzer, Elizabeth A. Raetz, Mignon L. Loh, Leonard A. Mattano, Catherine Cole, (unknown), (unknown), (unknown), Nyla A. Heerema, (unknown), Julie M. Gastier‐Foster, Michael J. Borowitz, Brent L. Wood, Cheryl L. Willman, Naomi Winick, Stephen P. Hunger, William L. Carroll	231
12	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331 2014 ·Blood ·Leonard A. Mattano, Meenakshi Devidas, Alison M. Friedmann, Elizabeth A. Raetz, Mignon L. Loh, Patrick J. Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie M. Gastier‐Foster, Nyla A. Heerema, Nina S. Kadan‐Lottick, Yousif Matloub, David T. Marshall, Linda C. Stork, Brent L. Wood, Naomi Winick, Stephen P. Hunger, William L. Carroll, Kelly W. Maloney	13
13	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712 2011 ·Journal of Clinical Oncology ·Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, R. Kanti, Richard A. Larson, John C. Byrd	102
14	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study 2009 ·Journal of Clinical Oncology ·Kirk R. Schultz, W. Paul Bowman, Alexander Aledo, William B. Slayton, Harland N. Sather, Meenakshi Devidas, Chenguang Wang, Stella M. Davies, Paul S. Gaynon, Michael E. Trigg, Robert Rutledge, Laura Burden, (unknown), Andrew J. Carroll, Nyla A. Heerema, Naomi Winick, Michael J. Borowitz, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta	436
15	Deregulated CDC25A Expression Promotes Mammary Tumorigenesis with Genomic Instability 2007 ·Cancer Research ·Dipankar Ray, Yasuhisa Terao, (unknown), (unknown), Francesco J. DeMayo, Konstantin Christov, Nyla A. Heerema, Roberta Franks, Sophia Y. Tsai, Eleftherios T. Papoutsakis, Hiroaki Kiyokawa	55
16	Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions 2004 ·Blood ·Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, (unknown), Jennifer Webb, Mollie E. Moran, Margaret S. Lucas, Thomas S. Lin, (unknown), John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd	306
17	Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphomas of Children and Adolescents 2004 ·Journal of Pediatric Hematology/Oncology ·Mark A. Lones, Warren G. Sanger, Michelle M. Le Beau, Nyla A. Heerema, Richard Sposto, Sherrie L. Perkins, Jonathan D. Buckley, Marshall E. Kadin, Carl R. Kjeldsberg, Anna T. Meadows, Stuart E. Siegel, Jonathan L. Finlay, Sharon Bergeron, Mitchell S. Cairo	37
18	Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies 1998 ·Cancer ·Fatih M. Uckun, James B. Nachman, Harland N. Sather, Martha G. Sensel, Peter Kraft, Peter G. Steinherz, Beverly Lange, Raymond J. Hutchinson, Gregory H. Reaman, Paul S. Gaynon, Nyla A. Heerema	1
19	Multiplex PCR: Critical Parameters and Step-by-Step Protocol 1997 ·IUScholarWorks (Indiana University) ·Octavian Henegariu, Nyla A. Heerema, S. R. Dlouhy, Gail H. Vance, P. H. Vogt	33
20	Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. 1987 ·Journal of Clinical Investigation ·Fatih M. Uckun, John H. Kersey, K Gajl-Peczalska, Nyla A. Heerema, Arthur J. Provisor, D. Haag, Gerald Gilchrist, C. W. Song, D Arthur, James S. Roloff	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact